Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Newman

Geriatric Medicine Bonsall, CA Medical Doctor

NPI 1922082189 CMS profile 314212

31457 Lake Vista Cir, Bonsall, CA 92003

Open in the dashboard

General payments

$3,468

181 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Newman of Bonsall, CA is reported in the CMS Open Payments database as having received $3,468 across 181 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $120 1
2023 General $97 1
2020 General $2,044 110
2019 General $1,207 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Newman
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to Jeffrey Newman were reported at $120. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year Jeffrey Newman Geriatric Medicine median Middle half National median
2019 $1,207 $96 $28–$339 $163
2020 $2,044 $99 $28–$262 $114
2021 $0 $94 $27–$318 $132
2022 $0 $103 $34–$338 $149
2023 $97 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $120 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $635 24 payments
  2. Allergan Inc. $345 26 payments
  3. Vanda Pharmaceuticals Inc. $333 13 payments
  4. Sanofi-Aventis U.S. LLC $223 17 payments
  5. GlaxoSmithKline, LLC. $215 14 payments
  6. Lilly USA, LLC $213 7 payments
  7. Mylan Specialty L.P. $157 7 payments
  8. Amarin Pharma Inc. $146 9 payments
  9. Kowa Pharmaceuticals America, Inc. $134 8 payments
  10. Pfizer Inc. $111 6 payments
  11. Other $956 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,451 180 payments
  2. Consulting Fee $17 1 payment
Products named General payments · program years 2019–2025
  1. FARXIGA $635 24 payments
  2. SYMBICORT $338 2 payments
  3. HETLIOZ $333 13 payments
  4. BREZTRI AEROSPHERE $180 1 payment
  5. VRAYLAR $172 14 payments
  6. MOVANTIK $157 1 payment
  7. Yupelri $157 7 payments
  8. Perforomist $157 7 payments
  9. Livalo $134 8 payments
  10. Vascepa $128 8 payments
  11. Other $2,487 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

215

Median for Family Practice: 1,826

Drug cost

$6,056

Median for Family Practice: $120,094

Branded share of claims

5.1%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 11 $2,763
Levothyroxine Sodium Generic 45 $652
Tamsulosin Hcl Generic 20 $601
Oxybutynin Chloride Generic 18 $395
Omeprazole Generic 28 $389
Atorvastatin Calcium Generic 16 $363
Lisinopril Generic 21 $254
Metformin Hcl Generic 18 $217
Spironolactone Generic 16 $172
Potassium Chloride Generic 11 $128

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

181 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record